INTERPACE BIOSCIENCES, INC.

PARSIPPANY, NJ · Medtech · Public

Molecular diagnostic tests for cancer risk evaluation

Claim this profile

Follows are private to you and power your alerts

Updated · interpace.com

Sector
Medtech
Headquarters
PARSIPPANY, NJ
Latest Form D
$47M, Oct 2024
Total capital
$113M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$113M
5 Form D · last Oct 2024
24 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

20172018201920202021202220232024FEDERAL ↑EQUITY ↓Cumulative $113M3rd Form D$14M4th Form D$47M5th Form D$47M
2017201920212023FEDERAL ↑EQUITY ↓Cumulative $113M4th Form D$47M5th Form D$47M

Latest events

  • Private capital raisedForm D · SEC · 5th filing$47M
  • Private capital raisedForm D · SEC · 4th filing$47M
  • Private capital raisedForm D · SEC · 3rd filing$14M
  • Private capital raisedForm D · SEC · 2nd filing$5M
  • Private capital raisedForm D · SEC · 1st filing$111K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Founders and team

From SEC Form D filings
  • Christopher W. McCarthyExecutive OfficerNamed in SEC Form D filings
  • Edward R. ChanDirectorNamed in SEC Form D filings
  • Eric J. LevDirectorNamed in SEC Form D filings
  • Felice J. Schnoll-SussmanDirectorNamed in SEC Form D filings
  • Fortunato Ron RoccaDirectorNamed in SEC Form D filings
  • Fortunato W. Ron RoccaDirectorNamed in SEC Form D filings
Show all 16 people
  • Gregory J. RichardExecutive OfficerNamed in SEC Form D filings
  • Jack E. StoverExecutive Officer, DirectorNamed in SEC Form D filings
  • James E. EarlyExecutive OfficerNamed in SEC Form D filings
  • Joseph E. KeeganDirectorNamed in SEC Form D filings
  • Laurence R. McCarthyDirectorNamed in SEC Form D filings
  • Robert R. GormanDirectorNamed in SEC Form D filings
  • Stephen J. SullivanDirectorNamed in SEC Form D filings
  • Thomas W. BurnellExecutive Officer, DirectorNamed in SEC Form D filings
  • Thomas J. FreeburgExecutive OfficerNamed in SEC Form D filings
  • Vijay W. AggarwalDirectorNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

  • CARLSMED, INC.Similar federal contract value in Medtech · null in contracts
  • Nalu MedicalSimilar federal contract value in Medtech · null in contracts
  • NURO INCSimilar federal contract value in Medtech · null in contracts
  • Respicardia, Inc.Similar federal contract value in Medtech · null in contracts
  • SetPoint Medical CorpSimilar federal contract value in Medtech · null in contracts
  • HOLOGIC INCSimilar federal contract value in Medtech · null in contracts

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .